SierraSil Joint Formula 14 as an Ergogenic Aid to Performance in Athletes
SierraSil as an Ergogenic Aid to Performance in Athletes
1 other identifier
interventional
10
1 country
1
Brief Summary
The purpose of this study is to examine whether supplementation with SierraSil can improve anaerobic power and reduce muscle fatigue in a group of well-trained athletes. A secondary purpose is to examine the effect of SierraSil on the severity of delayed onset muscle soreness.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started May 2014
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
August 27, 2013
CompletedFirst Posted
Study publicly available on registry
August 30, 2013
CompletedStudy Start
First participant enrolled
May 1, 2014
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 1, 2014
CompletedStudy Completion
Last participant's last visit for all outcomes
September 1, 2014
CompletedJuly 15, 2015
July 1, 2015
4 months
August 27, 2013
July 13, 2015
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
change in total anaerobic capacity
change from baseline at 3 weeks
Study Arms (2)
SierraSil
EXPERIMENTALSierraSil will be given in a dosage of 3 to 5, 667 mg capsules, according to body weight, daily for 3 weeks.
Placebo
PLACEBO COMPARATORThis is a sugar pill and will be given in a dosage of 3 to 5 capsules daily for 3 weeks.
Interventions
Eligibility Criteria
You may qualify if:
- no contraindications to strenuous exercise
You may not qualify if:
- muscle or joint injury
- taking any form of anti-inflammatory or pain medication
- females due to the variability that might be introduced due to the phases of the menstrual cycle
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
University of British Columbia
Vancouver, British Columbia, V6T 1Z3, Canada
Study Officials
- PRINCIPAL INVESTIGATOR
Donald C. McKenzie, MD, PhD
University of British Columbia
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, INVESTIGATOR
- Purpose
- TREATMENT
- Intervention Model
- CROSSOVER
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
August 27, 2013
First Posted
August 30, 2013
Study Start
May 1, 2014
Primary Completion
September 1, 2014
Study Completion
September 1, 2014
Last Updated
July 15, 2015
Record last verified: 2015-07